No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial

HIV Medicine

Volumn 11, Issue 8, 2010, Pages 493-501

  Calmy, A ^a,b   Bloch, M ^c   Wand, H ^d   Delhumeau, C ^b   Finlayson, R ^e   Rafferty, M ^a   Norris, R ^a   Hirschel, B ^b   Cooper, D A ^a,d   Carr, A ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Holdsworth House General Practice   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e Taylor Square Private Clinic ^*  (Australia)

Author keywords

HIV lipoatrophy; Limb fat; Pravastatin; Uridine

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; CHOLESTEROL; DIDANOSINE; FOSAMPRENAVIR PLUS RITONAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOMAXX; PRAVASTATIN; SODIUM; TENOFOVIR; UNCLASSIFIED DRUG; URIDINE; VIRUS RNA;

ABDOMINAL SUBCUTANEOUS FAT; ADULT; ARTICLE; BICARBONATE BLOOD LEVEL; BODY FAT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EVENING DOSAGE; GASTROENTERITIS; HEART BLOCK; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTRAABDOMINAL FAT; LIMB; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THIRD DEGREEE; THROMBOCYTOPENIA; TREATMENT DURATION;

ABSORPTIOMETRY, PHOTON; ADIPOSITY; ADULT; ANTI-RETROVIRAL AGENTS; ANTICHOLESTEREMIC AGENTS; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; EXTREMITIES; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; PRAVASTATIN; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; URIDINE;

EID: 77955251067     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00817.x     Document Type: Article

References (24)

1. Carr A, Samaras K, Burton S. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
2. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet 1999, 353:2093-2099.
3. Saint-Marc T, Partisani M, Poizot-Martin I. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long term nucleoside analogue therapy. AIDS 1999, 13:1659-1667.
4. Brinkman K, Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opin Infect Dis 2000, 13:5-11.
5. Mallon PW, Sedwell R, Rogero G. Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction. J Infect Dis 2008, 198:1794-1803. for the Rosey Investigators
6. Calmy A, Hirschel B, Cooper DA, Carr A. A new era of antiretroviral toxicity. Antiviral Ther 2009, 14:165-179.
7. Haubrich RH, Riddler SA, Di Rienzo AG. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009, 23:1109-1118. for the AIDS Clinical Trials Group (ACTG) A5142 Study Team
8. Martin A, Smith D, Carr A. Changes in lipodystrophy 2 years after switching from thymidine nucleoside analogues to abacavir. AIDS 2004, 18:1029-1036.
9. John M, McKinnon EJ, James IR. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003, 33:29-33.
10. Carey DL, Baker D, Rogers GD. A randomized, multicenter, open-label study of poly-l-lactic acid for HIV-1 facial lipoatrophy. J Acquir Immune Defic Syndr 2007, 46:581-589. for the Facial LipoAtrophy Study in HIV investigators.
11. Carr A, Workman C, Carey D. No effect of rosiglitazone for HIV-1 lipoatrophy: a randomised, double-blind, placebo-controlled trial. Lancet 2004, 363:429-438.
12. Slama L, Lanoy E, Valantin MA. Effect of pioglitazone on HIV-1 related lipoatrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antiviral Ther 2008, 13:67-76.
13. Walker UA, Langmann P, Miehle N, Zilly M, Klinker H, Petchner F. Beneficial effects of oral uridine in mitochondrial toxicity. AIDS 2004, 18:1085-1086.
14. Sutinen J, Walker UA, Sevastianova K, Hakkinen AM, Ristola M, Yki-Jarvinen H. Uridine supplementation increases subcutaneous fat in patients with HAART-associated lipodystrophy (HAL) - a randomized, placebo-controlled trial. Antiviral Ther 2007, 12:97-105.
15. McComsey GA, O Riordan M, Setzer B, Lebrecht D, Baron E, Walker UA. Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices. Eur J Clin Nutr 2008, 62:1035-1037.
16. Mallon PWG, Miller J, Kovacic JC. Effects of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men: a randomised, placebo-controlled study. AIDS 2006, 20:1003-1010.
17. Macallan DC, Baldwin C, Mandalia S. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials 2008, 9:254-268.
18. Riddler SA, Haubrich R, DiRienzo AG. Class sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008, 358:2095-2106.
19. Darnowski JW, Handschumacher RE. Tissue uridine pools: evidence in vivo of a concentrative mechanism for uridine uptake. Cancer Res 1986, 46:3490-3494.
20. Van Groeningen CJ, Peters GJ, Pinedo HM. Modulation of fluorouracil toxicity with uridine. Semin Oncol 1992, 2((Suppl 3)):148-154.
21. Carr A, Workman C, Carey D. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. The Lancet 2004, 363:429-438. for the Rosey investigators
22. Banash M, Goetze O, Knyhala K. Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients. AIDS 2006, 11:1554-1557.
23. Venhoff N, Venhoff AC, Jayewardene AL, Aweeka F, Lebrecht D, Walker UA. Pharmacokinetics of zidovudine and lamivudine during oral uridine supplementation with NucleomaxX. J Acquir Immune Defic Syndr 2008, 48:114-115.
24. Ridker PM, Danielson E, Fonseca FA. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373:1175-1182. for the JUPITER Trial Study Group.